Despite the promising potential of CHK1 inhibitors, there are several challenges in their clinical application. One major issue is the potential for toxicity in normal cells, as CHK1 also plays a vital role in normal cell cycle regulation. Another challenge is the development of resistance to CHK1 inhibitors, which can occur through various mechanisms, such as compensatory activation of parallel pathways or mutations in CHK1 itself.
